ORMP
OramedFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
Current thesis
Bull case assumes positive clinical/regulatory outcomes and at least one commercial partnership that validates the oral-protein delivery platform and materially expands addressable market, justifying a significant multiple re-rate and >70% upside from the anchor. Reviewer note: recent aggregator snippets show consensus targets near $3.25–3.32 (sanity check vs.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.1.
What can break
Clinical trial failure or negative data
Momentum
13
Value
44
Sentiment
34
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.30 · Bull $6.00 · Bear $1.80
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2026-01-09 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-21
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $6.25
Why
Momentum13 · Δ7d -
Value44 · Δ7d +0.1
Sentiment34 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
13
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
44
39% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-0.0
Sentiment
34
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade F. Momentum 13.1 / Value 44.3 / Sentiment 33.5
Fundamentals (TTM)As of 2026-07-21
Fundamentals (TTM)
As of 2026-07-21
Market Cap
$164.52M
Beta
1.33
Shares Out
40.93M
P/E (TTM)
2.9
P/S (TTM)
58.91
P/FCF (TTM) · Derived
-18.66
Rev YoY
-100.0%
EPS YoY
-592.3%
Gross Margin
-5.4%
Op Margin
-650.5%
Net Debt
-$125.07M
Current Ratio
6.45
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology